Summary In 65 patients with systemic breast cancer, a biochemical response index using three tumour markers in combination, carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3) and erthrocyte sedimentation rate (ESR), allowed objective biochemical assessment of response to endocrine therapy. Changes in these three markers at 2, 4 and 6 months showed a highly significant correlation with UICC assessed response at 6 months. At 4 months, changes in these three markers resulted in a selectivity of 93%, with a sensitivity of 92% and a specificity of 82%. Survival of groups of patients assessed biochemically or by UICC criteria for non-progression or progression showed no significant difference.
Summary In 65 patients with systemic breast cancer, a biochemical response index using three tumour markers in combination, carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3) and erthrocyte sedimentation rate (ESR), allowed objective biochemical assessment of response to endocrine therapy. Changes in these three markers at 2, 4 and 6 months showed a highly significant correlation with UICC assessed response at 6 months. At 4 months, changes in these three markers resulted in a selectivity of 93%, with a sensitivity of 92% and a specificity of 82%. Survival of groups of patients assessed biochemically or by UICC criteria for non-progression or progression showed no significant difference.
The advantages of the biochemical assessment are that it is objective and reproducible. The assessment gives similar information to the UICC assessment but can be carried out earlier. Changes in the three markers appears to reflect the dynamics of change in tumour mass in response to systemic therapy in contrast to the UICC criteria which reflect structural change.
Endocrine therapy for advanced breast cancer was first introduced by a surgeon in Scotland in 1896 (Beatson, 1896) yet we still lack truly objective criteria by which to assess therapeutic response. Even the criteria most widely used at present, i.e. International Union Against Cancer (UICC) criteria, acknowledge their inherent subjectivity by requiring external review of response data. More recently clinicians have investigated the potential role of tumour markers both in the diagnosis of breast cancer and in measuring response to therapy.
There is no single, ideal tumour marker for breast cancer. Combinations of tumour markers, including carcinoembryonic antigen (CEA), have been investigated to increase the sensitivity of detecting metastases by biological markers (Franchimont et al., 1976; Coombes et al., 1977a; Coombes et al., 1977b; Cowen et al., 1978; Cove et al., 1979; Coombes et al., 1981; Bezwoda et al., 1981) . A much smaller number of studies have reported on the use of CEA in combination with other biological markers in measuring response (Woo et al., 1978; Waalkes et al., 1978; Haagensen et al., 1978; Silva et al., 1982) .
Following the discovery of monoclonal antibodies by Kohler and Milstein (1975) , monoclonal antibodies have been raised to a number of breast cancer associated antigens. Serum CEA has been examined in combination with a number of monoclonal antibodies raised to tumour associated antigens -e.g. MAM-6 antigen, 11 5D8 (Hilkens et al., 1987) , antigen (Hayes et al., 1986; Fujino et al., 1986; Pons-Anicet et al., 1987; Kallioniemi et al., 1988; Tondini et al., 1988; Delarue et al., 1988) and mammary serum antigen (MSA) (Stacker et al., 1988) . Other newer monoclonal antibodies have been reported such as MCA (Stahli et al., 1989) , CA 549 (Bray et al., 1989) and CA M26 and CA M29 (van Ramp et al., 1989) . However to date the value of these newer monoclonal antibodies either in combination with 'or compared to CEA has not been reported.
In Nottingham we have previously shown in a retrospective analysis (Williams et al., 1990) and prospectively confirmed (Nicholson et al., 1981; Nicholson et al., 1986 (Hayward et al., 1977) . Three patients were unassessable for response by UICC criteria. Seventeen patients who died within 3 months of starting endocrine therapy all had UICC assessable disease; the main site of disease at presentation being liver (n = 7), lung/pleura (n = 5), bone and lung (n = 1), bone (n = 2) or lymph nodes (n = 2). Direct (Howell et al., 1988; Robertson et al., 1989) . In analysing the correlation between biochemical marker movement after 2, 4 or 6 months therapy and UICC assessed response we combined the categories of complete response (CR), partial response (PR) and static disease (SD) into 'non-progressive' disease group and compared this with the group of patients showing progression.
Biochemical assessment of response Biochemical response to therapy in patients with metastatic breast cancer is assessed in the same manner for all serum markers studied in this unit -i.e. any change in marker while the patient is on therapy is related to the pre-treatment baseline value of the marker and the interassay coefficient of variation (CV) of the marker (10% for all three markers in this study). A cut-off level for each individual marker of the mean ± 2 SD of the normal control group was calculated. Patients who never showed an elevation of the marker above this level were regarded as biochemically unassessable for that particular marker. Patients who started with an initially elevated value which fell to below the cut-off level or patients with an initial value above the cut-off level which subsequently decreased by more than the interassay CV (10%) for that particular marker were regarded as showing a decreasing marker level indicative of 'biochemical response'. As in our previous reports (Williams et al., 1990; ) CEA and ESR were scored -2 and -I respectively. CA15-3 was scored the same as CEA (i.e. -2). Patients with an initial pretreatment value below the cut-off level which subsequently rose above the cut-off level or patients with an initial value above the cut-off level which subsequently increased above the interassay CV (10%) for that particular marker were regarded as showing an increasing marker level indicative of 'biochemical progression' (all markers scored + 2). Patients with levels which started and remained above cut-off but which moved by less than the interassay CV (10%) were regarded as 'biochemically stable' and scored + 1.
Change in the concentration of each serum marker was scored as summarised in Table I. Since a 10% change in marker concentration may seem small, the data were also analysed using a 20% change in each marker as significant to see if this made any difference to the results. The scores for each individual marker were added together to give the response index score.
Statistical analyses Data were analysed using the statistical package SPSSX-21 (SPSS, 1986 initially at -20°C and subsequently transferred to storage at -70°C. All samples were assayed blind of clinical information on aliquots thawed once only. Marker concentrations in each specimen were always measured in duplicate.
CA15-3 CA15-3 was measured using the commercially available CIS ELSA kit (CIS, High Wycombe, UK). Intra- assay variation was estimated using sera containing low (mean 7.8 U ml-1), medium (mean 30 U ml-') and high values (mean 723 U ml-') of CA15-3: the C.Vs were 13.2%, 5.0% and 3.1% respectively. The inter-assay C.V. estimated using the medium value of CA15-3 was 9.2%.
Carcinoembryonic antigen (CEA) CEA was measured in aliquots of serum using the commercially available CIS ELSA kit (CIS, UK). The intra-and inter-assay coefficients of variation (CVs) were 6.9% and 7.1% respectively.
Erythrocyte sedimentation rate (ESR) Two ml of freshly aspirated blood was placed in a tube containing EDTA. ESR was measured by the Westergen technique.
Results
Of the 65 patients who were both assessable for response and survived for > 3 months three (5%) showed a complete response to systemic endocrine therapy, 19 (29%) showed a partial response, and 10 (15%) had static disease. Thirtythree patients (51%) showed progression of disease within 6 months. Therefore 49% of patients had non-progressive disease (response and static) for a minimum of 6 months and 51% patients progressed within 6 months of therapy. UICC assessed response was compared with the biochemical index score using -(1) CEA and ESR together, (2) CEA and CA15-3 in combination as omission of ESR would allow the index to be calculated from serum samples alone (fresh or frozen) and (3) CEA, CA15-3 and ESR. The previously set cut-off levels (see Table I ) were used for all three markers (i.e. CEA 6 ng ml', CA15-3 33 U ml-' and ESR 20 mm h-'). As noted above a change in a marker from the baseline value of > ± 10% (or > ± 20%) was regarded as significant. Scores for each individual marker were added together to give a 'biochemical response score'.
CEA and ESR Changes in CEA and ESR in combination showed a highly significant correlation with UICC response at 2, 4 and 6 months (Table II) . Reanalysis using a change in the baseline value of > ± 20% as significant gave a similar result at 2, 4 and 6 months (Table IIb) . Changes in serum CEA and CA15-3 in combination showed a highly significant correlation with UICC response at 2, 4 and 6 months (Table III) . Reanalysis using a change in the baseline value of > ± 20% as significant gave a similar result at 2, 4 and 6 months ( Table IIIb) .
CA 15-3, CEA and ESR Using CA15-3, CEA and ESR in combination the biochemical score at 2, 4 and 6 months correlated significantly with UICC assessed response at 6 months ( Table  IV) . The analysis was repeated taking a change from the baseline of > ± 20% as significant. The results are shown in Table V . There was no difference in the correlation with the UICC response whether a change in each marker of > ± 10% (Table IV) or > ± 20% (Table V) was used in calculating the biochemical score.
Correlation between the biochemical response score and UICC assessed response appeared better using the biochemical scores at 4 or 6 months than at 2 months. However even comparing the 4 month biochemical assessment with the UICC assessed response at 6 months there was still seven patients out of 53 who were classified differently by the two methods as assessment (Table IV) . To identify if either method of assessment was significantly different from the other, the assessments of response by UICC at 6 months and biochemical score at 4 months were plotted against survival from commencing systemic therapy. Figure 1 showing survival by the four recognised UICC criteria (complete response (CR), partial response (PR), static disease (SD) or progressive disease (PD)) confirmed that in this group, patients with static disease at 6 months had similar survival Since the survival of patients with partial response and .
-- Table VII . Selectivity, sensitivity, specificity and accuracy were highest using the CEA/CA15-3/ESR combination; assessment at 4 months was better than at either 2 or 6 months.
Discussion
Recent reports have questioned the value of CEA in addition to CA15-3 which was individually the more sensitive marker both in diagnosis of systemic disease (Hayes et al., 1986; Delarue et al., 1988; Tondini et al., 1988) and in assessing response to therapy (Tondini et al., 1988) . It has been suggested that CEA added nothing to CA15-3 alone neither in the diagnosis of metastatic disease (Delarue et al., 1988) nor in monitoring response to therapy (Tondini et al., 1988) . We have shown that by changing the marker combination and by increasing the number of markers, the number of patients who become 'biochemically' assessable increased significantly (Tables VI and VII) .
If patients showed elevation of any of the three markers, the biochemical response index score correlated very well with UICC assessed response whatever marker or combination of markers were assessable. There was only slight differences in the overall accuracy for each marker combination (Table  VII) . The improvement produced by combining markers was in increasing the number of patients who became biochemically assessable (Table VI) . Although the number of patients biochemically assessable was not statistically higher using CEA and CA15-3 in combination against CA15-3 alone (X2 = 2.37; 1 d.f.; P > 0.05), similar comparison between CEA, CA15-3 and ESR vs CA15-3 alone (X2= 8.41; 1 d.f.; P <0.01) did show a significant increase in the number of patients biochemically assessable. The overall x2 value shown (Table VI) confirmed that the increase in the number of biochemically assessable patients by combining the markers was statistically significant (X2 = 37.36; 5 d.f.; P <0.001). Previous reports all show an increase (though not significant) in the number of patients assessable using CEA and CA15-3 compared to CA15-3 alone: this trend in all the reported studies, together with the results shown in this study suggest that lack of numbers is the most likely explanation why this consistent increase in the number of patients assessable by CEA and CA15-3 in combination vs CA15-3 alone has not been shown to reach statistical significance in any individual study. In this prospective study, selectivity, sensitivity and specificity were all highest using the CEA/CA15-3/ESR combination (Table VII) ; at 4 months, selectivity was 93%, sensitivity 92%, specificity 82% and overall accuracy 87%. The use of this combination of three tumour markers in patients with systemic breast cancer appears to provide an assessment of response to endocrine therapy which gives similar information to the UICC assessment but at an earlier date and is both objective and reproducible.
Changes in the markers reported in this study correlated with UICC response irrespective of whether the size of the marker change was 10% or 20% of the baseline values. Changes in the markers at 2 or 4 months predicted response at 6 months as assessed by UICC criteria. Changes in the three markers (CEA, CA15-3 and ESR) appear to reflect the dynamics of change in tumour mass in response to therapy in contrast to the UICC criteria which reflect structural change. We have shown assessment by markers would not have been detrimental to patient survival. On the contrary changing therapy as a result of increasing marker concentrations before structural changes are seen may allow the clinician time to find a therapy which will induce a therapeutic response resulting in a consequent improvement in survival. We are currently testing this hypothesis in a controlled clinical trial.
